What sector does Krystal Biotech, Inc. belong to?

Krystal Biotech, Inc. operates in the Health Care sector, specifically the Biotechnology industry, and is listed on the US markets.

What is the current share price of KRYS?

As of the latest available quote, KRYS traded at $347.00. This price is delayed and cached for about 15 minutes.

What is the P/E ratio of KRYS?

Krystal Biotech, Inc. has a price-to-earnings (P/E) ratio of about 43.48. The P/E ratio compares the share price to earnings per share and is most useful when compared with sector peers and the company's own history.

What is the market capitalisation of KRYS?

The market capitalisation of Krystal Biotech, Inc. is approximately $10.39B.

Is Krystal Biotech, Inc. profitable?

For its latest reported financial year, Krystal Biotech, Inc. recorded a net profit margin of about 52.64%.

Does KRYS pay a dividend?

Krystal Biotech, Inc. does not currently show a dividend yield in our data.

What is the return on equity (ROE) of KRYS?

Krystal Biotech, Inc. has a return on equity (ROE) of about 15.07%. ROE measures how much profit a company generates relative to shareholders' equity.

What is the 52-week high and low of KRYS?

Over the past 52 weeks, KRYS has traded between a low of $145.46 and a high of $382.54.

Krystal Biotech, Inc.

KRYS US Health Care Biotechnology

S&P 600

$347.00

+0.42%

Delayed · cached 15 min

Fair value analysis

KRYS

Krystal Biotech, Inc.

$347.00

Close used for this calculation

$121.79Fair value

Financial DNA Score

Profitability · Returns · Balance Sheet · Efficiency · Growth

57/100

Profitability25/25

Returns8/25

Balance Sheet18/25

Efficiency6/25

Growth12/25

Good

Quality radar

Consensus fair value

$121.79

Above FV

▼ -64.9% against the close used

Model range $82.59 – $205.20

The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.

Price target range & 52-week position

Bear$82.59Fair value$121.79Bull$205.20

FairClose

52-week traded range

52W low $143.6852W high $378.15

The 52-week range is measured from the stored price history, not estimated.

Valuation summary

Trading above the consensus fair value

Krystal Biotech, Inc. closed at $347.00, 184.9% above the consensus fair value of $121.79 drawn from 8 valuation models.

Financial DNA score 57/100 — Good. P/E of 50.7x against the 20x sector multiple the P/E model uses.

Quantitative summary only — not investment advice.

All valuation models

DCF Valuation

$125.22

-63.9%

Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10

g=9%, r=10%, tg=3%, n=10yr

Graham Number

$82.59

-76.2%

√(22.5 × EPS × BVPS)

EPS=6.84, BVPS=44.32 · outside Graham range (P/E 50.7, P/B 7.8) — asset-light, treat as a rough floor

P/E Fair Value

$136.80

-60.6%

EPS × 20x (sector P/E)

EPS=6.84, Sector P/E=20x

Peter Lynch (PEG)

$205.20

-40.9%

EPS × Growth% (PEG = 1 is fair)

EPS=6.84, g=30%

EV/EBITDA

$100.39

-71.1%

(EBITDA × 18x − Net Debt) ÷ Shares

EBITDA=167.02M

Book Value (P/B)

$100.49

-71.0%

BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]

BVPS=44.32, ROE=15.1%, g=6%, r=10%

Reverse DCF

$347.00

+0.0%

Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV

Implied: 19.7% | Historical: 40%

Margin of Safety

$86.15

-75.2%

Avg(DCF, Graham, P/E) × 75% (25% safety buffer)

Avg fair value=114.87, MoS=25%

Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.

Educational data only. Not a recommendation to buy, sell or hold any security.

Fair value analysis

Consensus fair value

Price target range & 52-week position

Valuation summary

All valuation models

Equity Timer